Myriad Genetics (MYGN) Enterprise Value (2009 - 2026)

Myriad Genetics has disclosed Enterprise Value across 18 years of filings, most recently posting -$124.4 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 35.51% year-over-year to -$124.4 million; the TTM figure through Mar 2026 stood at -$124.4 million (down 35.51% YoY), while the FY2025 annual figure was -$149.6 million, down 46.09% from the prior year.
• Enterprise Value rose to -$124.4 million in Q1 2026, from -$149.6 million in the prior quarter.
• Over the last five years, Enterprise Value for MYGN reached as high as -$74.4 million in Q2 2025 and fell as low as -$267.4 million in Q1 2022.
• The 5-year median for Enterprise Value is -$114.9 million (2022), against an average of -$129.1 million.
• Annual changes were most pronounced in 2022 — Enterprise Value tumbled 51.85% — and 2023, when it soared 70.57%.
• A 5-year view of Enterprise Value shows it stood at -$114.9 million in 2022, then dropped by 22.63% to -$140.9 million in 2023, then climbed by 27.32% to -$102.4 million in 2024, then tumbled by 46.09% to -$149.6 million in 2025, then rose by 16.84% to -$124.4 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$124.4 million, -$149.6 million, and -$145.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.